ROCHE HLDGS AG SPN ADR EACH REP 0.125GENUS (RHHBY)

30.53
0.02 0.07
OTC
Prev Close 30.51
Open 30.39
Day Low/High 30.29 / 30.55
52 Wk Low/High 25.25 / 33.77
Volume 570.12K
Exchange OTC
Shares Outstanding 5620.50B
Market Cap 177.38B
Div & Yield N.A. (N.A)

Latest News

Roche CEO Bullish on U.S. Drug Market

Roche CEO Bullish on U.S. Drug Market

Roche shares gain after the company's CEO says he's 'fully dedicated' to the key U.S. market.

Roche Shares Gain; CEO 'Fully Dedicated' to Key U.S. Market

Roche Shares Gain; CEO 'Fully Dedicated' to Key U.S. Market

Roche shares traded higher in Zurich on Wednesday after the company's CEO said he was bullish on its U.S. market.

Roche Posts Solid 2016 Profit, 2017 Outlook; Dividend Falls Short

Roche Posts Solid 2016 Profit, 2017 Outlook; Dividend Falls Short

Roche posted solid second-half earnings on Wednesday and said it expects single-digit sales growth in 2017, guidance that was largely in line with analysts' forecasts.

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

FDA Grants Priority Review For Genentech's Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, A Form Of Vasculitis

FDA Grants Priority Review For Genentech's Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, A Form Of Vasculitis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Is It Time to Buy Beaten-Down Bristol-Myers Squibb Stock?

Is It Time to Buy Beaten-Down Bristol-Myers Squibb Stock?

Bristol-Myers Squibb stock has fallen by 35% in the last six months.

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.

Breakthrough Development For Americans With Suspected Heart Attack - Next Generation Troponin T Test From Roche Cleared By FDA

Breakthrough Development For Americans With Suspected Heart Attack - Next Generation Troponin T Test From Roche Cleared By FDA

New Troponin T 9-minute test offers greater sensitivity in the diagnosis of myocardial infarction

European Pharma Shares Hammered After Trump Press Conference Attack

European Pharma Shares Hammered After Trump Press Conference Attack

European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.

Bristol-Myers and AstraZeneca Take Beatings

Bristol-Myers and AstraZeneca Take Beatings

It happened in the wake of Merck's latest drug approval.

FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review In Additional Type Of Advanced Bladder Cancer

FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review In Additional Type Of Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Roche Gains FDA Clearance For 18-Minute Anti-Mullerian Hormone Test To Assess Ovarian Reserve

Roche Gains FDA Clearance For 18-Minute Anti-Mullerian Hormone Test To Assess Ovarian Reserve

New blood test measures the remaining egg supply of women who are planning to become pregnant

FDA Approves Genentech's Lucentis® (Ranibizumab Injection) For Myopic Choroidal Neovascularization

FDA Approves Genentech's Lucentis® (Ranibizumab Injection) For Myopic Choroidal Neovascularization

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Genentech's Emicizumab For Hemophilia A Meets Primary Endpoint In Phase III Study

Genentech's Emicizumab For Hemophilia A Meets Primary Endpoint In Phase III Study

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary endpoint has been met for the Phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or...

Positive Phase III Results Of Genentech's Investigational Medicine OCREVUS™ (Ocrelizumab) Published In New England Journal Of Medicine

Positive Phase III Results Of Genentech's Investigational Medicine OCREVUS™ (Ocrelizumab) Published In New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that data from three Phase III studies of its investigational medicine OCREVUS™ (ocrelizumab) - the OPERA I and OPERA II studies in...

FDA Extends Review Of Application For OCREVUS™ (Ocrelizumab)

FDA Extends Review Of Application For OCREVUS™ (Ocrelizumab)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Genentech's Avastin® (Bevacizumab) Plus Chemotherapy For A Specific Type Of Advanced Ovarian Cancer

FDA Approves Genentech's Avastin® (Bevacizumab) Plus Chemotherapy For A Specific Type Of Advanced Ovarian Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Good Start Genetics Announces Marketing Agreement With Roche Diagnostics For Carrier Screening In The United States

Good Start Genetics Announces Marketing Agreement With Roche Diagnostics For Carrier Screening In The United States

Collaboration Marries Good Start's Proprietary Technology with Roche Diagnostics' Commercial Expertise for Broad Market Reach

Genentech's Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan

Genentech's Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the positive, pivotal Phase III GALLIUM study that compared Gazyva ® (obinutuzumab) plus chemotherapy followed by Gazyva...

Roche Launches DISCOVERY 5-Plex Procedure For Cancer Research Applications

Roche Launches DISCOVERY 5-Plex Procedure For Cancer Research Applications

Fully automated fluorescent multiplex procedure enables researchers to investigate up to five biomarkers on one tissue slide

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

In a few weeks, investors will know if Lilly's solanezumab is a groundbreaking treatment for Alzheimer's or another drug casualty to a disease that has eluded pharmaceutical companies for years.

Phase III GiACTA Study Shows Genentech's Actemra® Is Superior To Steroids Alone In Maintaining Steroid-Free Remission For People With Giant Cell Arteritis

Phase III GiACTA Study Shows Genentech's Actemra® Is Superior To Steroids Alone In Maintaining Steroid-Free Remission For People With Giant Cell Arteritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III GiACTA study, which evaluated Actemra ® (tocilizumab) in people with GCA.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.

European Drug Companies Get an Injection From Trump Victory

European Drug Companies Get an Injection From Trump Victory

The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.